ASTRAZENECA AB
🇪🇸Spain
A Phase III, Randomized, Double blind, Placebo controlled, Multi centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum based, Concurrent Chemoradiation Therapy (eVOLVE Cervical)
Phase 3
Not yet recruiting
- Conditions
- D069 Cervix, unspecifiedCervix, unspecifiedD069
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele
Phase 2
Recruiting
- Conditions
- K75 NULL
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- AstraZeneca AB
- Target Recruit Count
- 1
- Registration Number
- PER-016-23